Canmab is a prescription medication containing trastuzumab, a monoclonal antibody used to treat certain types of breast cancer and gastric cancer.
Composition: Canmab contains 440mg of trastuzumab, a humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2).
Mechanism of Action: Trastuzumab works by binding to the HER2 receptor on the surface of cancer cells, which inhibits the growth and proliferation of these cells. It also blocks the signaling pathways that promote cancer cell growth and survival.
Uses: Canmab is used to treat:
- HER2-positive metastatic breast cancer (MBC) in combination with paclitaxel
- HER2-positive early breast cancer (EBC) in combination with adjuvant chemotherapy
- HER2-positive gastric cancer in combination with chemotherapy
Dosage: The recommended dosage of Canmab is:
- 440mg administered as an intravenous infusion every 3 weeks in combination with chemotherapy
Side Effects: Common side effects of Canmab may include:
- Infusion-related reactions (e.g. fever, chills, headache)
- Fatigue
- Nausea and vomiting
- Diarrhea
- Abdominal pain
- Changes in liver function tests (LFTs)
- Changes in blood cell counts
- Cardiac arrhythmias (e.g. heart palpitations, atrial fibrillation)
- Respiratory problems (e.g. dyspnea, cough)
Recommendation: Canmab is recommended for patients who have been diagnosed with HER2-positive breast cancer or gastric cancer. It is important to discuss the potential benefits and risks of Canmab with your doctor before starting treatment.
Important Note:
- Canmab is a prescription medication and should only be used under the guidance of a healthcare provider.
- Patients taking Canmab should not take any other medications that may interact with trastuzumab, such as anticancer medications or certain antibiotics.
- Patients taking Canmab should report any changes in their blood cell counts, including low white blood cell counts, to their doctor.
- Patients taking Canmab should not breastfeed during treatment and for at least 6 months after stopping treatment.
- Patients taking Canmab should not donate blood or sperm during treatment and for at least 6 months after stopping treatment.
Reviews
There are no reviews yet.